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Abstract 
Objective  
Endothelial cells store von Willebrand factor (VWF) in rod-shaped secretory organelles, called 
Weibel-Palade bodies (WPBs). WPB exocytosis is coordinated by a complex network of Rab 
GTPases, Rab-effectors and SNARE proteins. We have previously identified STXBP1 as the link 
between the Rab27A-Slp4-a complex on WPBs and the SNARE proteins syntaxin-2 and -3. In 
this study we investigate the function of syntaxin-3 in VWF secretion.  
Approach and Results 
In human umbilical vein endothelial cells (HUVECs) and in blood outgrowth endothelial cells 
(BOECs) from healthy controls endogenous syntaxin-3 immunolocalized to WPBs. A detailed 
analysis of BOECs isolated from a patient with variant microvillus inclusion disease (MVID), 
carrying a homozygous mutation in STX3 (STX3-/-), showed a loss of syntaxin-3 protein and 
absence of WPB-associated syntaxin-3 immunoreactivity. Ultrastructural analysis revealed no 
detectable differences in morphology or prevalence of immature or mature WPBs in control 
versus STX3-/- BOECs. VWF multimer analysis showed normal patterns in plasma of the MVID 
patient, and media from STX3-/- BOECs, together indicating WPB formation and maturation are 
unaffected by absence of syntaxin-3. However, a defect in basal as well as Ca2+- and cAMP-
mediated VWF secretion was found in the STX3-/- BOECs. We also show that syntaxin-3 
interacts with the WPB-associated SNARE protein VAMP8. 
Conclusions 
Our data reveal syntaxin-3 as a novel WPB-associated SNARE protein that controls WPB 
exocytosis.  
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Introduction  
 
Von Willebrand factor (VWF) is a multimeric adhesive glycoprotein that is critically involved in 
hemostasis by mediating adhesion of platelets to sites of vascular damage and by acting as a 
chaperone for coagulation factor VIII in plasma. The importance of VWF for vascular 
homeostasis is illustrated by the pathophysiological phenotypes that are associated with 
abnormal levels of circulating VWF. Low levels of VWF are associated with bleeding, such as in 
the inherited bleeding disorder Von Willebrand disease (VWD), while elevated levels of VWF are 
associated with increased risk of thrombosis and cardiovascular disease.1 The majority of VWF 
is synthesized by endothelial cells, where it is stored in secretory organelles called Weibel-
Palade bodies (WPBs). VWF, together with a number of inflammatory and angiogenic mediators, 
is rapidly released from WPBs upon shear stress or damage to the vessel wall.2  
The mechanisms that regulate biogenesis and exocytosis of WPBs are complex and 
poorly understood. During biogenesis and maturation, WPBs recruit a set of Rab GTPases 
(Rab27A, Rab3B/D, Rab15) and Rab-effectors (MyRIP, Slp4-a, Munc13-4), that mediate 
interactions with the cytoskeleton and plasma membrane (PM). Recruitment of these molecules 
coincides with the acquisition of WPB secretion competence and provides the link with Soluble 
NSF Attachment Protein REceptor (SNARE) complex proteins.3–9 SNARE complexes are 
molecular machines that catalyze the fusion of lipid bilayers, which plays a central role in the 
exocytosis of secretory vesicles. They typically consist of four SNARE helices: 1 provided by a v-
SNARE/R-SNARE on the donor compartment (VAMPs) and 3 Q-SNAREs provided by a t-
SNARE complex (1 by syntaxins and 2 by SNAP25 homologues) on the acceptor compartment. 
Assembly of v- and t-SNAREs into a parallel 4 helix bundle produces a mechanical force that 
brings the vesicle and target membranes in close proximity, lowering the energetic barrier for 
fusion. A number of SNARE and SNARE associated proteins have been implicated in WPB 
exocytosis.10–14 Despite this, we currently do not know the exact composition of the WPB 
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exocytotic machinery and how all these individual components together orchestrate WPB 
release. Recently, syntaxin-3 was found as part of a complex with STXBP1 and the Rab27A-
effector Slp4-a, which both have been identified as positive regulators of WPB exocytosis. 7,12 
In this study we show that syntaxin-3 localizes to WPBs. VWF secretion is significantly 
impaired in ex vivo STX3-/- endothelial cells derived from a patient with variant microvillus 
inclusion disease (MVID), whereas WPB abundance and morphology are unaffected. We 
identified VAMP8, another WPB localized SNARE, as an interaction partner of syntaxin-3. 
Together, the data identify syntaxin-3 as a new component of the SNARE machinery regulating 
WPB exocytosis and VWF secretion.  
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Materials and Methods 
 
The whole-proteome analysis .raw MS files and search/identification files obtained with 
MaxQuant are available through the ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange.org/cgi/GetDataset) via the PRIDE partner repository15 
with the dataset identifier PXD006176. 
 
Antibodies 
Antibodies used in this study are listed in Supplementary Table 1. 
 
Cell culture and blood outgrowth endothelial cell (BOEC) isolation 
Pooled, cryo-preserved primary human umbilical vein endothelial cells (HUVECs) were obtained 
from Promocell (Heidelberg, Germany) and were cultured as described.12 BOECs were isolated 
as previously described and cultured in EGM-2 medium (Lonza, Basel, Switzerland, CC-3162) 
supplemented with 18% FCS (Bodinco, Alkmaar, Netherlands).12 Experiments were always 
performed at passage 5-6. Venous blood was drawn from an individual with variant Microvillous 
Inclusion Disease (MVID) caused by a homozygous 2-bp insertion (c.372_373dup, 
p.Arg125Leufs*7) in STX3 (patient 2 in 16), and from both parents. Blood from an additional 
variant MVID patient with a homozygous nonsense mutation (c.739C>T, p.Arg247*) in STX3 
(patient 1 in 16) and the mother of the patient was drawn, but isolation of BOECs was only 
successful for the heterozygous mother. Control BOECs from healthy donors were isolated from 
the internal blood donor system at Sanquin Blood Supply. The patient’s parents signed an 
informed consent form for participation. The study was conducted in accordance with the 
Declaration of Helsinki. 
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Immunocytochemistry 
Endothelial cells were grown on gelatin-coated glass coverslips (Marienfeld, Lauda-Königshofen, 
Germany). Cells were fixed at room temperature with EM-grade 4% formaldehyde (Electron 
Microscopy Sciences, Hatfield, USA) in PBS for 15 min followed by simultaneous 
permeabilization and quenching using 0.2% saponin, 50 mM NH4Cl in PBS. Immunostaining 
was performed in PGAS (PBS, 0.2% gelatin, 0.02% NaN3, 0.02% saponin). Immunostained cells 
were mounted in Mowiol 40-88® (Sigma-Aldrich, Steinheim, Germany, 324590) and images 
were acquired by confocal microscopy using a Leica SP8 (Leica Microsystems, Wetzlar, 
Germany). 
 
Subcellular fractionation  
HUVECs were grown to confluency and after 4 days they were homogenized using a ball-
bearing homogenizer (Isobiotec, Heidelberg, Germany) essentially as described previously.17 
Subcellular fractions were obtained by density gradient ultracentrifugation using a Beckmann 
Optima ™ LX-100 XP ultracentrifuge equipped with a Ti50.2 fixed angle rotor. Briefly, 
homogenates were fractionated by two subsequent Percol (GE Healthcare, Eindhoven, 
Netherlands) density gradients followed by one Nycodenz (Progen Biotechnik, Heidelberg, 
Germany) density gradient.17  Percoll fractions and Nycodenz fractions containing the WPBs 
were identified by VWF ELISA.18 Selected fractions were analyzed by immunoblotting for 
syntaxin-3.  
 
Immunoblotting 
Endothelial cells were grown to confluency and lysed in NP-40 based lysis buffer (1% NP-40, 
10% glycerol, 1 mM EDTA, 1 mM EGTA, 50 mM Tris HCL, 100 mM NaCL), supplemented with 
Complete protease inhibitor cocktail (Roche, 05056489001). Proteins were separated on a 
Novex® NuPAGE® 4-12% Bis-Tris gel (ThermoFisher, NP0321/NP0323) and transferred onto a 
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nitrocellulose membrane (iBlot Transfer Stack, ThermoFisher, IB3010). Membranes were 
blocked with Odyssey blocking buffer (LI-COR Biosciences, Lincoln, USA,LI 927) and probed 
with primary antibodies followed by IRDye conjugated secondary antibodies. IRDye conjugated 
antibodies were visualized by LI-COR Odyssey Infrared Imaging System (LI-COR Biosciences). 
Image Studio Lite (V4.0, LI-COR Biosciences) was used to analyze band intensities, when 
needed intensities were normalized to the intensity of α-tubulin which was used as a loading 
control. 
 
Whole-proteome analysis of BOECs.  
BOECs were cultured in 10 cm culture dishes in triplicate. Upon confluency, cells were rinsed 3x 
in PBS and subsequently scraped in 100 µl SDS lysis buffer consisting of 4% SDS, 100 mM 
DTT, 100 mM Tris.HCl pH 7.5, supplemented with MS grade Halt protease and phosphatase 
inhibitor cocktail (Thermo Scientific, 78440). Next, cell lysates were incubated for 5 minutes at 
95°C, sonicated using a Branson Sonifier 250 (Branson Ultrasonics S.A., Geneva, Switzerland) 
and centrifuged for 10 minutes at 16,000g. The cleared lysates were obtained and the protein 
concentration was determined by Bradford. 50 μg of protein was processed into tryptic peptides 
using the Filter Aided Sample Preparation method.19 10 μg peptides were desalted and 
concentrated using Empore-C18 StageTips and eluted with 0.5% (v/v) acetic acid, 80% (v/v) 
acetonitrile as described before.20,21 Sample volume was reduced by SpeedVac and 
supplemented with 2% (v/v) acetonitrile, 0.1% (v/v) TFA to a final volume of 5 μl. Three μl was 
injected in the Mass Spectrometer (Orbitrap Fusion, Thermo Scientific, Waltham, MA, USA).  
Tryptic peptides were separated by nanoscale C18 reverse chromatography coupled online to 
an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific) via a nanoelectrospray ion 
source (Nanospray Flex Ion Source, Thermo Scientific), using the same settings as described 
in 21. All MS data were acquired with Xcalibur software (Thermo Scientific).  
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The RAW mass spectrometry files were processed with the MaxQuant computational platform, 
1.5.2.8.22 Proteins and peptides were identified using the Andromeda search engine by querying 
the human Uniprot database (downloaded February 2015).23 Standard settings with the 
additional options match between runs, Label Free Quantification (LFQ), and unique peptides for 
quantification were selected. The generated ‘proteingroups.txt’ table was filtered for reverse hits, 
‘only identified by site’ and potential contaminants using Perseus 1.5.1.6. The LFQ values were 
transformed in log2 scale. Samples were grouped per BOEC donor (STX3-/- patient, 4 healthy 
controls) (5 groups, 3 samples per group) and proteins were filtered for at least 3 valid values in 
at least one of the 5 groups. Missing values were imputed by normal distribution (width = 0.3, 
shift = 1.8), assuming these proteins were close to the detection limit. Global changes in protein 
levels were assessed employing four separate volcano plots where the syntaxin-3 patient 
BOECs were pair wise compared with the healthy control BOECs (FDR 0.05, S0: 0.4). Proteins 
with a significantly changed level were defined as proteins with a significantly changed 
expression in all four pair wise comparisons.  
The .raw MS files and search/identification files obtained with MaxQuant have been deposited in 
the ProteomeXchange Consortium (http://proteomecentral.proteom 
exchange.org/cgi/GetDataset) via the PRIDE partner repository15 with the dataset identifier 
PXD006176. 
 
Electron microscopy 
BOECs were grown in a petri dish to 5 days post-confluence and were fixed with Karnovsky’s 
fixative followed by 1% osmiumtetroxide post fixation,  en-bloc staining with Ultrastain1 (Leica 
Microsystems) and dehydration by ethanol series. Beem capsules were filled with EPON and the 
open side of the capsules were positioned on the fixed cells. After polymerization of the EPON, 
beem capsules were snapped off the surface of the wells of the culture dish. Ultrathin sections 
(70 nm) parallel to the surface of the beem specimen containing the cultured cells were made on 
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a Reichert Ultracut S (Leica Microsystems). Sections were post stained with uranylacetate and 
lead citrate. Electron microscopy images were obtained in a Fei Tecnai Twin transmission 
electron microscope (FEI, Eindhoven, Netherlands) operating on 120 kV using a Gatan OneView 
(Gatan, Pleasanton, USA) camera. About 2100 pics per stitch were taken on binning 2. 
Overlapping images were collected and stitched together into a big image as described.24 Single 
WPB images were taken from 7 different cells from stitches of both healthy control BOECs and 
STX3-/- BOECs (control: n=135, STX3-/-: n=128). All images were randomized after which 6 
researchers independently scored the maturation status of all 263 WPB images. Images that 
were not unanimously  recognized as WPBs were excluded (31 from control, 18 from stitch 
STX3-/-), which led to a final maturity scoring of 104 WPBs from healthy control BOECs and 110 
from STX3-/- MVID BOECs. 
 
Secretion assay  
Endothelial cells were grown in 6-well wells or on 24 mm polyester Transwell membranes with 
0.4 µm pores (3450, Costar) and cultured at full confluence for 4-5 days. Unstimulated VWF 
release was determined in conditioned EGM-18 medium after 24 hour incubation. Stimulated 
VWF release was assayed following a 15 minute pre-incubation in serum-free (SF) medium 
M199 (ThermoFisher, 22340) supplemented with 0.2% (w/v) BSA (Merck, 112018). Cells were 
stimulated in SF-medium supplemented with 0.1-100 µM histamine (Sigma-Aldrich, H7125), 10 
µM forskolin (Sigma-Aldrich, F6886) with 100 µM IBMX (Sigma-Aldrich, I7018), or vehicle 
(unstimulated) for 30 minutes, unless stated otherwise. Lysates were made in SF-media 
supplemented with 1% Triton X-100 and protease inhibitors. Polarized VWF secretion was 
assayed essentially as described25 and conditioned media were collected separately from the 
top (apical) and bottom compartment (basolateral). VWF and VWFpp levels were determined by 
ELISA. 
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VWF and VWFpp ELISA 
For determination of VWF secretion and intracellular content a sandwich ELISA was performed 
using (0.5 µg/well) rabbit polyclonal anti-hVWF as coating antibody and HRP-conjugated rabbit 
polyclonal anti-hVWF (0.5 µg/ml) for detection. Secreted and intracellular VWFpp was detected 
by sandwich ELISA using mouse monoclonal anti-hVWFpp (1.0 µg/well) as coating antibody and 
HRP-conjugated mouse monoclonal anti-hVWFpp (0.125 µg/ml) for detection. Blocking, washing 
and detection steps were performed in TWEB buffer (0.1% Tween-20, 0.2% gelatin, and 1 mM 
EDTA in PBS). HRP activity was measured by colorimetric detection of ortho-phenylenediamine 
(OPD) conversion using a Spectramax Plus 384 microplate reader (Molecular Devices, 
Sunnyvale, USA). Normal plasma from a pool of 30 donors served as a standard for 
determination of VWF antigen levels in plasma samples.26 For lysates and media samples 
concentrated conditioned media from HEK293Ts stably expressing human wildtype VWF27, 
which was calibrated against the plasma standard, was used as a standard.  
 
DNA construct and transfection  
For construction of mEGFP tagged to the N-terminus of human STX3 the STX3 coding 
sequence was amplified with RBNL175 (5’-GGGCGCGCCTGGTGGGGCCATGAAGGA 
CCGTCTGGAGCAGCTG-3’) and RBNL176 (5’-GCGGCCGCCTGCTCGTCCATTAATT 
CAGCCCAACGGAAAGTCC-3’) using a human STX3 cDNA clone (clone ID 3010338, Thermo 
Scientific) as template. The 908 bp PCR product containing the entire STX3 coding sequence 
was cloned in frame behind mEGFP in the mEGFP-LIC vector by ligation independent cloning, 
resulting in mEGFP-STX3. STX3 and VAMP8 were cloned into a lentiviral vector by digestion of 
the inserts from mEGFP-STX3 using BsrGI and NotI or from pEGFP-VAMP8 28 (a kind gift from 
Thierry Galli; Addgene #42311) using BsrGI and MluI. Fragments were inserted into the 
previously described LVX-mEGFP-LIC backbone, using the same restriction enzymes, 
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respectively.12  To construct lentiviral myc-STX3 the 10 residue myc-epitope from myc-LIC 7 was 
used to replace mEGFP in LVX-mEGFP-LIC through cut and paste cloning with SbfI and BsrGI, 
resulting in LVX-myc-LIC. STX3 was excised from LVX-mEGFP-STX3 using BsrGI and NotI and 
cloned in frame behind myc, resulting in LVX-myc-STX3. All constructs were verified by 
sequence analysis. Transfection of HUVECs was performed by nucleofection as described.29 
Lentivirus was produced in HEK293T cells cultured in EGM18 as described.12 Puromycin was 
used to select for transduced endothelial cells.  
 
Immunoprecipitation  
ECs expressing lentivirally transduced mEGFP-fusion proteins were lysed in lysis buffer (0.5% 
NP40, 10mM Tris.HCl (pH7.5), 150 mM NaCl and 0.5 mM EDTA) supplemented with Complete 
Protease Inhibitor Cocktail. Lysates were incubated with magnetic GFP-nanobody beads (Allele 
Biotech, San Diego, USA, ABP-NAB-GFPM100) or blocked control beads (ABP-NAB-
MCNTRL5)  by rotation for 2 hours at room temperature. Alternatively, lysates of native HUVECs 
were lysed and incubated with magnetic protein G dynabeads (Thermo Scientific, 10004D) 
coupled with antibody as described in the figure. After incubation, beads were washed 4 times 
with lysis buffer. Co-immunoprecipitates and lysates were analyzed by immunoblotting. 
 
CRISPR/Cas9 engineering of BOECs.  
gRNAs were designed to exon 1 and exon 2 of the STX3 gene using the CRISPOR Design tool 
(http://crispor.tefor.net/crispor.py). gRNAs (gRNA-A exon 1: CTTCAGGATGAAGGACCG TC; 
gRNA-B exon 2: GACGAGTTCTTTTCTGAGGT) were selected based on the specificity score 
with the minimum amount of off-target effects and were subsequently cloned as hybridized 
oligos  (gRNA-A: RBNL358 5’- CACCGCTTCAGGATGAAGGACCGTC-3’ and RBNL359 5’-
AAACGACGGTCCTTCATCCTGAAGC-3’; gRNA-B: RBNL364 5’-CACCGGAC 
GAGTTCTTTTCTGAGGT-3’ and RBNL365 5’-AAACACCTCAGAAAAGAACTCGTCC-3’) into 
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BsmBI-digested LentiCRIPSR v2 vector 30 (a kind gift from Feng Zhang; Addgene #52961). 
BOECs were transduced with LentiCRISPR constructs containing gRNA-A or gRNA-B or without 
gRNA insertion (control) as described above. Puromycin selected cells were single cell sorted 
using an antibody against VE-cadherin and plated in 96-well format. Clonal colonies were tested 
for the expression of syntaxin-3 by immunoblot and STX3 null clones were expanded. To identify 
the mutations in STX3, genomic DNA was isolated using the DNeasy Blood and Tissue kit 
(QIAGEN, Venlo, NL) from the STX3-/- clones. PCR products amplified using primers for exon 1 
(RBNL366: 5’-CGGACGCTCCTCCTAGCTAG-3’ and RBNL367: 5’-GTGGTGAAGGGACCCCTG 
AC-3’) and exon 2 (RBNL368: 5’-CCCAGCAATTGGTAGAGCTAGG-3’ and RBNL402: 5’-CATG 
GTTGTGATCCTATGGTTGATTCTG-3’) were subjected to Sanger sequencing and Next 
Generation Sequencing. 
 
Statistical analysis 
Statistical analysis was by two-tailed t-test using GraphPad Prism 7.04 (Graphpad, La Jolla, 
CA), either paired or unpaired as mentioned in the Figure legends. Prior to performing a paired t-
test normality was confirmed using the Shapiro-Wilk test on small (N=3-6) sample sizes. Prior to 
performing an unpaired t-test normality was approached by a log-transformation and an F-test 
was used to confirm equal variance in larger data sets (N<100). Significance values are shown 
in the Figures or in Figure legends. Data are shown as mean ± SEM. 
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Results 
The SNARE-protein syntaxin-3 is found on WPBs. 
In an unbiased proteomic pull down screen for endothelial Slp4-a interaction partners, we have 
previously identified STXBP1, together with syntaxin-2 and syntaxin-3.12 Here we determined the 
intracellular localization of syntaxin-3 in endothelial cells by immunocytochemistry. Endogenous 
syntaxin-3 immunoreactivity was primarily associated with WPBs in HUVECs (Figure 1A). In an 
earlier report Fu and colleagues looked at the cellular distribution of syntaxin-3 in lung 
microvascular endothelial cells and found that this protein was found primarily at cell-cell 
contacts and some intracellular punctate structures, but it remained inconclusive whether these 
represented WPBs.11 To further test the WPB localization of syntaxin-3 we undertook subcellular 
fractionation of HUVECs using density gradient ultracentrifugation.17,18 Consistent with 
localization on the WPB, syntaxin-3 immunoreactivity co-sedimented with VWF in WPB 
containing subcellular fractions (Figure 1B). This was further confirmed by expression of 
mEGFP-tagged or myc-tagged syntaxin-3 (Supplemental Figure I & II), which labels WPBs, 
although interestingly at ectopic expression a significant proportion was also found on the 
plasma membrane. Possibly, at normal expression levels, syntaxin-3 is targeted to the WPBs, 
but at expression levels higher than normal, such as achieved by overexpression of epitope-
tagged STX3, this SNARE can also be targeted to alternative locations. 
 
Ex vivo MVID blood outgrowth endothelial cells are an endothelial deficiency model for 
syntaxin-3. 
To assess the function of syntaxin-3 we established an ex vivo patient-derived model of 
syntaxin-3 deficiency using blood outgrowth endothelial cells (BOECs) from an MVID patient 
with a loss-of-function mutation in STX3. MVID is a rare but severe congenital gastrointestinal 
disorder that manifests itself by chronic diarrhea, malabsorption, metabolic acidosis and severe 
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dehydration. The abnormal morphology of the enterocytes, which involves microvillus atrophy, 
intracellular microvillus inclusion bodies and loss of intestinal epithelial cell polarity, is caused by 
defective membrane trafficking events as a result of genetic defects in (primarily) MYO5B and 
STXBP2.31,32 Recently, two atypical MVID patients have been described with homozygous loss-
of-function mutations in STX3 (Figure 2A).16 Both patients and several heterozygous, non-
affected family members participated in our study. Table 1 shows the VWF:Ag levels in plasma, 
which are moderately lower in both patients. Blood outgrowth endothelial cells were isolated 
from peripheral blood mononuclear cells, which was successful for all participants except patient 
2. In BOECs from patient 1, who carries a homozygous frame-shifting 2-bp insertion leading to a 
premature stop (c.372_373dup, p.Arg125Leufs*7) in exon 6 of STX3, we were unable to detect 
syntaxin-3 in its full length or predicted truncated form. BOECs from both heterozygous parents 
and also the mother of patient 2, who has a heterozygous nonsense mutation leading to a 
premature stop (c.739C>T, p.Arg247*) in exon 9 of STX3, contained approximately 50% 
reduced levels of syntaxin-3 (Figure 2B). This was further confirmed by mass spectrometry 
analysis of the whole proteome of MVID patient BOECs, which was compared to that of 4 
healthy control BOECs (Supplemental Figure III). Interestingly, 5 out of 6 peptides that were 
found for syntaxin-3 in the healthy control BOECs mapped in the area before the truncation, 
however we were unable to accurately detect these in the MVID patient BOECs (not shown). 
Most probably, both mutations lead to depletion of syntaxin-3 due to either reduced protein 
stability 16 or nonsense mediated decay of the mutant transcripts. Consistent with the absence of 
syntaxin-3 expression, WPBs in BOECs from the MVID patients showed a loss of syntaxin-3 
immunoreactivity, while the abundance, distribution and size of WPBs appeared unaltered 
(Figure 2C and Supplemental Figure IV & V). CRISPR/Cas9-engineered STX3-/- BOECs 
(Supplemental Figure VI) also showed loss of syntaxin-3 immunoreactivity but like in the patient 
BOECs this did not lead to altered morphology of the WPBs (Supplemental Figure VII).  
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Syntaxin-3 deficiency does not perturb WPB formation or recruitment of key membrane 
components. 
SNAREs are key regulators of protein trafficking by facilitating membrane fusion between 
organelles or during exocytosis. As syntaxin-3, in contrast to syntaxin-411,33, localizes to WPBs 
rather than the plasma membrane, we investigated whether syntaxin-3 functions in WPB 
formation and maturation. Throughout its life cycle the WPB can engage in several membrane 
fusion steps that contribute to biogenesis, (membrane) content acquisition or exocytosis.34 
Biogenesis of secretory organelles is generally thought to involve a number of discrete steps: 
cargo condensation in the TGN (1), budding of nascent / immature secretory granules (ISGs) 
from the TGN (2), homotypic fusion of ISGs (3) and removal of excess membrane (4).35 To 
which extent this also applies to WPB biogenesis is still under debate, but there is evidence for 
the existence of immature WPBs as well as fusion of WPBs.36–38 We carried out ultrastructural 
analysis of the morphology of large numbers of mature and immature WPBs using TEM stitches 
of control and STX3-/- BOECs. The numbers and morphometric characteristics of mature WPBs, 
characterized by intensely condensed cargo, were very similar in both WT and STX3-/- samples. 
When measured, no significant difference in WPB length (WT: 889 nm +/- 335 nm vs. STX3-/-: 
991 nm +/- 414 nm) but a small, statistically significant difference in width (WT: 173 nm +/- 52 
nm vs. STX3-/-: 188 nm +/- 61 nm) was observed (Figure 3A-D). Immature WPBs, characterized 
by one or a few discrete VWF tubules loosely surrounded by membrane (Figure 3Aiii, Biii), were 
also found in similar proportions in WT and STX3-/- samples (Figure 3D). WPBs containing 
hinges (e.g. Figure 3Aii, Bii) are thought to result from head-on fusion between WPBs.37 Hinged 
WPBs were routinely observed in both WT and STX3-/- samples. We also observed normal VWF 
multimers in plasma from the MVID patient and his parents (Figure 3E & Supplemental Figure 
VIII), as well as stored in and secreted from cultured STX3-/- BOECs (Figure 3F).  
To determine if syntaxin-3 plays a role in delivery of key membrane components to the WPB we 
first studied the localization of the tetraspanin CD63. The endosome-lysosome marker CD63 is 
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thought to be delivered to WPBs through an AP-3- and annexin-8-dependent interaction/fusion 
with endosomal compartments.39–41 Comparison of control and STX3-/- BOECs showed no 
obvious differences in CD63 localization (Figure 4). In both cases CD63 was found in 
abundance in WPBs and also in VWF-negative spherical organelles, most probably representing 
late endosomes, which in some cases were also syntaxin-3 positive (Figure 4). Localization of 
the WPB v-SNAREs, VAMP3 and VAMP833, (Supplemental Figure IX) and the WPB membrane 
associated proteins P-selectin, Rab27A and Slp4-a (Supplemental Figure X-XI) were also 
unaffected in STX3-/- BOECs.3,7,42,43 Taken together our data suggest that syntaxin-3 does not 
play a key role in the formation and maturation of WPBs and their content, nor in the recruitment 
of membrane components to the WPB. 
 
Ex vivo MVID endothelial cells deficient for syntaxin-3 have impaired basal and hormone-
evoked WPB exocytosis. 
To investigate the role of syntaxin-3 in WPB exocytosis, we measured hormone-evoked VWF 
propeptide (VWFpp) release from STX3-/- BOECs. We chose to assay VWFpp because after 
release from the WPB, VWFpp has a lower retention to the cellular surface than VWF and is 
therefore a more direct measure of WPB degranulation.44,45 Intracellular levels of VWFpp were 
comparable between STX3-/- BOECs and those from a healthy control donor (Figure 5A). 
However, STX3-/- BOECs showed a significantly reduced release of VWFpp in unstimulated 
conditions (Figure 5B). Also, STX3-/- BOECs showed a clear stimulus-induced secretion defect: 
upon stimulation with both Ca2+- (histamine) as well as cAMP-mediated (forskolin) 
secretagogues a significant decrease in VWFpp release was observed (Figure 5C) and this was 
augmented when lower concentrations of histamine were used (Figure 5D). Essentially similar 
results were obtained when assaying for secretion of mature VWF (Supplemental Figure XII)  
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In a recent report it was shown that unstimulated/basal as well as stimulus-induced VWF 
secretion are primarily directed towards the endothelial lumen while constitutive secretion of 
VWF is mostly directed to the basolateral side of the endothelium.25 To test whether syntaxin-3 
contributes to the polarity of VWF secretion we performed Transwell secretion assays. 
(Supplemental Figure XIII). Interestingly, while the decrease in stimulated secretion in MVID 
BOECs is on both sides, the decrease observed in unstimulated VWF secretion was almost 
entirely caused by a deficit on the apical side (Supplemental Figure XIII Bi-ii and Ci-ii). 
Proportionally, while both stimulus-induced and unstimulated VWF release are both released 
primarily in the apical direction, the polarity of unstimulated release is lost in MVID BOECs 
(Supplemental Figure XIII Biii-iv and Ciii-iv). This suggests that syntaxin-3 supports apically 
directed basal release of WPBs, which during strong activation such as upon 100 μM histamine 
stimulation, can be partially compensated for, possibly by other SNARE complexes. 
To study the mechanism by which syntaxin-3 can promote WPB exocytosis we looked for 
interactors that have been previously implicated in WPB exocytosis, such as the WPB 
associated v-SNAREs VAMP3 and -8 and the t-SNARE SNAP23.14,42 Co-immunoprecipitation 
experiments using mEGFP-syntaxin-3 as bait showed that syntaxin-3 predominantly interacts 
with SNAP23 and VAMP8 and to a lesser extent with VAMP3 (Figure 5E). Similarly, reciprocal 
pull down using mEGFP-VAMP8 showed co-precipitation of syntaxin-3, but also syntaxin-4 
(Figure 5F). This was further confirmed using precipitation of endogenous syntaxin-3 and 
syntaxin-4 from endothelial cells. VAMP8 and SNAP23 co-precipitated with both endogenous 
syntaxin-3 and syntaxin-4 (Figure 5G). However, we were unable to confirm endogenous 
VAMP3 interaction with either syntaxin-3 or syntaxin-4.  
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Discussion  
Circulating levels of VWF are determined by environmental as well as genetic factors, with the 
heritability of variation being estimated up to 75%.46–48 In approximately 30% of cases low VWF 
is caused by mutations outside the VWF gene, implying that other genetic loci are involved in 
regulation of VWF levels.49 Genome-wide association studies (GWAS) for genetic determinants 
of VWF levels have identified a number of new regulators that are suggested to affect secretory 
processes (STXBP5 and STX2)13,50, arguing that SNARE-mediated exocytosis of WPBs is a 
significant determinant of VWF levels. In this study we have characterized a new component of 
the WPB regulatory machinery, syntaxin-3, previously identified as a downstream target of the 
Rab27A – Slp4-a – STXBP1 complex.12   
The main finding of our study is the identification of SNARE protein syntaxin-3 as a 
secretory granule localized regulator of WPB exocytosis. The SNARE fusion machinery 
underlies exocytosis in all secretory cells. Endothelial cells express several members of the 
SNARE complex, which includes a mixture of t-SNAREs; SNAP23, syntaxin-2, -3 and -4, and 
WPB-localized v-SNAREs; VAMP3 and VAMP8.11,12,14,33 The SNARE complexes formed are in 
turn regulated by SNARE-associated proteins including STXBP1, STXBP3 and STXBP5.11–13 
However, the precise number and composition of SNARE complexe(s) and their specific roles in 
controlling VWF secretion remains unclear. In the context of such a complex cocktail of SNAREs 
it can prove challenging to single out the contribution of an individual component, especially 
since residual levels of SNAREs that remain upon depletion using RNA interference have been 
reported to suffice for their function.51 Therefore we took the opportunity to study the role of 
syntaxin-3 in a patient-derived endothelial model of complete syntaxin-3 deficiency using blood 
outgrowth endothelial cells from a MVID patient with mutations in STX3. Our results show that 
complete loss of syntaxin-3 leads to a significant attenuation of VWFpp and VWF secretion.  
In syntaxin-3 deficient MVID patients circulating levels of VWF are at the low end of the 
normal range for the general population, although not associated with bleeding complications. 
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Plasma levels of VWF are thought to be maintained by unstimulated VWF secretion by the 
endothelium, which arises primarily from basal release of WPBs.25,52 In line with this, analysis of 
STX3-/- BOECs showed a small but statistically significant reduction in unstimulated VWF and 
VWFpp secretion (Figure 5B). There was also clear defect of stimulus-induced secretion in 
STX3-/- BOECs: we observed a significant reduction of VWFpp and VWF secretion upon 
challenging with Ca2+- or cAMP-mediated secretagogues. However, WPB release was not 
completely abolished which most likely reflects functional redundancy through syntaxin-3-
independent SNARE complexes that are able to partially compensate for the loss of syntaxin-3. 
Because VWF secretion from the endothelium is such a critically important process, as 
illustrated by patients with type III VWD, a high degree of redundancy in the molecular regulation 
of VWF secretion may reflect an evolutionary drive to maintain this vital process. Indeed, of the 
SNARE-(associated) mediators of WPB release identified so far, the consequence of depletion 
of any one factor leads, in the majority of cases, to only a partial reduction of stimulated WPB 
release.7,11,12,14,33 This may also explain why genetic disorders affecting a single component of 
the WPB exocytosis machinery are often not accompanied by significant hemostatic 
complications or why genetic variations such as identified in GWAS studies are associated with 
modest effects on VWF levels.53–55 Employing several distinct SNARE complexes potentially 
also enables the endothelium to have greater control over its secretory response (e.g. release of 
different subsets of WPBs), support different modes of exocytosis or control release at specific 
sites. Attempts to experimentally rescue the secretory defect in STX3 deficient BOECs using 
ectopically expressed STX3 were unsuccessful and even attenuated stimulated VWF release in 
both STX3-/- and control BOECs (data not shown), possibly due to mistargeting of a pool of 
epitope-tagged STX3 (Supplemental Figures I-II). Whether this was the result of the epitope-tag 
or the inability to experimentally control the ectopic expression levels remains unclear, but this 
may be further indication that the proper function of syntaxin-3 in WPB exocytosis depends on 
its localization on the secretory vesicle. 
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Microvillus inclusion disease is characterized by a failure of enterocytes, polarized 
intestinal epithelial cells, to target microvilli to their apical surface. This manifests as a loss of 
brush-border microvilli, basolateral targeting of microvilli and the formation of microvillus 
inclusion bodies. Syntaxin-3, which contains an N-terminal apical targeting motif, is normally 
found at the apical side where it supports delivery of apical membrane proteins involved in the 
formation of microvilli. Loss of syntaxin-3, such as in the MVID patient from whom we 
established STX3-/- BOECs, leads to a loss of polarity and mistargeting of apical cargo to the 
basolateral side where syntaxin-4 is found.16,56–58 Endothelial cells also exhibit apical/basolateral 
polarity with the apical side facing the vessel lumen, while the basolateral side is connected to 
the subendothelial matrix. Recently, evidence has been presented that endothelial cells secrete 
high molecular weight VWF from a stored WPB pool predominantly at the apical side, where it is 
ideally positioned to support platelet adherence. In contrast, low molecular weight VWF is 
secreted constitutively at the basolateral side.25 The mechanisms that dictate this preference for 
the apical side are still unknown, but our data suggest that syntaxin-3 supports apical release of 
WPBs.  
Membrane fusion events in the regulated secretory pathway can be heterotypic (fusion 
between different compartments, i.e. WPB–PM) or homotypic (fusion of similar intracellular 
compartments, for example WPB-WPB). One previously described homotypic fusion mode is  
compound fusion, in which several WPBs fuse intracellularly prior to exocytosis. Upon 
compound fusion, enlarged, rounded structures are formed, termed “secretory pods”, that 
contain disordered VWF tubules.59,60 A related but distinct mode of WPB fusion, termed 
sequential or cumulative exocytosis, has recently been reported.61,62 In this mode a post-fusion 
WPB provides a membrane site for subsequent cumulative fusion of additional WPBs. The 
mechanisms underlying homotypic WPB fusion are not known, however, in mast and pancreatic 
acinar cells, cumulative fusion is the predominant form of exocytosis and has been studied more 
extensively. In both cell types syntaxin-3 is found on the secretory organelles.63,64 In acinar cells, 
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syntaxin-3 was found to pair with SNAP23 and VAMP8, the latter of which is also found on 
WPBs, while syntaxin-2 complexed with VAMP2 and SNAP23. During sequential exocytosis 
syntaxin-2 and syntaxin-3 containing SNARE machineries were found to support distinct steps: 
primary granules were released via syntaxin-2, while the subsequent secondary steps were 
dependent on syntaxin-3.65 A similar mechanism was described in insulin granule exocytosis 
from pancreatic beta cells, where syntaxin-3 regulates exocytosis of a secondary, “newcomer” 
granule.66 One difference between compound and cumulative fusion is the strength of stimulus 
required to set these pathways in motion: in eosinophils compound fusion becomes more 
prevalent in conditions of high stimulus while the incidence of cumulative fusion is increased at 
low levels of stimulus.67 In that respect it is noteworthy that at lower concentration of histamine 
the loss of syntaxin-3 leads to a more prominent decrease in VWFpp secretion. (Figure 5D and 
Supplemental Figure XIID).  
Taken together, our data identify syntaxin-3 as a novel WPB-localized regulator of VWF 
secretion which, depending on the degree of endothelial activation, takes a prominent role in 
WPB release at the apical side of endothelial cells. Based on its interactions with (WPB-
localized) SNAREs that have been previously implicated in VWF secretion, we speculate that a 
homotypic fusion mode of WPBs is the underlying mechanisms by which syntaxin-3 facilitates 
exocytosis (Figure 6). Future studies should address whether assembly of trans-complexes of t-
SNAREs and v-SNAREs on opposing WPBs contribute to homotypic fusion modes, such as 
compound or sequential/cumulative fusion.  
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Highlights 
• Syntaxin-3 is a Weibel-Palade body associated SNARE protein that interacts with other 
WPB associated SNAREs. 
• Blood outgrowth endothelial cells from a variant microvillus inclusion disease patient are 
an endothelial deficiency model for syntaxin-3. 
• Endothelial cells that are deficient for syntaxin-3 have impaired basal and stimulated 
VWF secretion.  
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Table 1. Levels of circulating VWF measured in MVID patients and relatives 
 
Subject VWF:Ag (IU/ml) 
Patient 1 (STX3-/-: c.372_373dup, p.Arg125Leufs*7) 0.6 
Mother of patient 1 (STX3+/-) 2.2 
Father of patient 1 (STX3+/-) 1.1 
Patient 2 (STX3-/-: c.739C>T, p.Arg247*) 0.6 
Mother of patient 2 (STX3+/-) 1.1 
  
   
   
   
   
   
Figure 6 
 
Supplemental Table I. Antibody reagents 
Target Species (isotype) Label Supplier Cat.nr / 
clone 
Use  
[concentration/dilution] 
VWF mouse (IgG2b) - described in 1 CLB-RAg20 IF [1:1000] 
syntaxin-3 rabbit - Synaptic Systems 110033 IF,WB [2 µg/ml] 
α-tubulin mouse (IgG1) - Sigma-Aldrich T9026 WB [1:1000] 
VWF rabbit - DAKO A0082 ELISA [6 µg/ml] 
VWF rabbit HRP DAKO A0082 ELISA [2 µg/ml] 
VWFpp mouse - described in 2 CLB-pro35 ELISA [1:2500] 
VWFpp mouse HRP described in 2 CLB-pro14-3 ELISA [1:2500] 
GFP rabbit  GeneTex GTX113617 WB [0.5 µg/ml] 
Slp4-a mouse (IgG1)  Santa Cruz sc-374544 IF [1 µg/ml] 
CD63 mouse (IgG1) AF488 Sanquin CLB-gran/12 IF [0.4 µg/ml] 
CD62P mouse (IgG1) AF488 AbD Serotec MCA796 IF [2 µg/ml] 
Rab27A rabbit  described in 3  IF [1:100] 
VAMP3 rabbit  Synaptic Systems 104203 WB [1 µg/ml], IF [2 µg/ml] 
VAMP8 rabbit  Synaptic Systems 104303 WB, IF [1 µg/ml] 
syntaxin-4 Mouse (IgG1)  BD Biosciences 610439 WB [0.25 ug/ml] 
SNAP23 rabbit  Synaptic Systems 111203 WB [1 µg/ml] 
VE-cadherin Goat  Santa Cruz sc-6458 IF [0.4 µg/ml] 
F-actin (Phalloidin) AF670 Tebu-Bio PHDN1-A IF [28 nM] 
c-myc Mouse (IgG1)  Invitrogen 13-2500 IF [2.5 ug/ml] 
rabbit IgG donkey 680LT Li-Cor 925-68023 WB [0.1 µg/ml] 
mouse IgG donkey 680LT Li-Cor 925-68022 WB [0.1 µg/ml] 
rabbit IgG donkey 800CW Li-Cor 925-32213 WB [0.1 µg/ml] 
mouse IgG donkey 800CW Li-Cor 925-32212 WB [0.1 µg/ml] 
rabbit IgG goat AF405 ThermoFisher A31556 IF [2 µg/ml] 
rabbit IgG chicken AF488 ThermoFisher A21441 IF [2 µg/ml] 
rabbit IgG goat AF568 ThermoFisher A11011 IF [2 µg/ml] 
rabbit IgG chicken AF647 ThermoFisher A21443 IF [2 µg/ml] 
mouse IgG chicken AF488 ThermoFisher A21200 IF [2 µg/ml] 
mouse IgG goat AF568 ThermoFisher A11004 IF [2 µg/ml] 
mouse IgG chicken AF647 ThermoFisher A21463 IF [2 µg/ml] 
goat IgG donkey AF488 ThermoFisher A11055 IF [2 µg/ml] 
goat IgG donkey AF568 ThermoFisher A11057 IF [2 µg/ml] 
goat IgG chicken AF647 ThermoFisher A21469 IF [2 µg/ml] 
 
  
Supplemental Figure I 
 
Supplemental Figure I. mEGFP-syntaxin-3 labels WPBs and plasma membrane. 48 
hours after Nucleofection with mEGFP-syntaxin-3 (green) HUVECs were fixed and 
immunostained for VWF (red). Boxed areas in the top panels are magnified below. Arrows 
indicate syntaxin-3 positive WPBs. 
  
Supplemental Figure II 
 
Supplemental Figure II. myc-STX3 labels WPBs and plasma membrane. 5 days after 
transduction with myc-syntaxin-3 BOECs were fixed and immunostained for VWF (red), 
syntaxin-3 (green) and myc (blue). Boxed areas in the panels are shown as magnifications, 
displaying membranous (1) and WPB (2) localization of myc-STX3. Arrowheads indicate 
syntaxin-3 positive WPBs. 
  
Supplemental Figure III 
 
Supplemental Figure III. BOECs from a 2-year old MVID patient with a homozygous 
STX3 mutation are devoid of syntaxin-3. (A) Differentially expressed proteins between the 
STX3-/- BOECs and 4 healthy control BOECs are shown in four separate volcano plots. N=3 
per patient/healthy control, FDR = 0.05 and S0 = 0.4. (B) Heat map and hierarchical 
clustering (based on average Euclidean distance and pre-processed with k-means) of 
proteins with significantly changed levels (defined as significantly changed expression in all 
four volcano plots of the STX3-/- BOECs and healthy control BOECs). Proteins are indicated 
by gene names. Heat map colors (see legend) are based on the z-scored LFQ data (log2). 
Supplemental Figure IV 
 
Supplemental Figure IV. Weibel-Palade body distribution is similar in control and 
syntaxin-3 deficient cells. Control and syntaxin-3 deficient MVID BOEC were culture at 
confluency for 4-5 days, fixed and immunostained for VWF (cyan) and VE-cadherin 
(magenta). Shown are single XY plane and orthogonal XZ and YZ projections with apical (A) 
and basolateral (B) directions indicated 
Supplemental Figure V  
Supplemenal Figure V: WPB distribution relative to actin cytoskeleton is unaffected by 
syntaxin-3 deficiency. Control and syntaxin-3 deficient MVID BOECs were cultured at 
confluency for 4-5 days, fixed and stained for filamentous actin (magenta) and VWF (cyan). 
Arrow heads indicate WPBs in contact with F-actin. 
  
 Supplemental Figure VI  
 
Supplemental Figure VI: CRISPR/Cas9-engineered STX3-/- BOECs. A) Syntaxin-3 
immunoblot showing syntaxin-3 expression in 2 selected control clones and lack of syntaxin-
3 expression in 2 selected STX3-/- CRISPR clones obtained by targeting exon 1 (STX3-/- A) or 
exon 2 (STX3-/- B). α-tubulin is shown as a loading control. B) DNA sequence analysis of the 
same clones, showing CRISPR events in exon 1 and 2 at the expected sites for double 
strand break close to the protospacer adjacent motif (PAM) site of the respective gRNA 
target sites. Predicted null mutations based on Sanger and Next Generation Sequencing of 
the clones are indicated in the chromatograms. 
  
Supplemental Figure VII 
 
Supplemental Figure XIII: Morphological analysis of CRISPR-engineered STX3-/- 
BOECs. Control and CRISPR STX3-/- BOEC clones were cultured at confluency for 4-5 days, 
fixed and immunostained for VWF, syntaxin-3 and VE-cadherin.  
Supplemental Figure VIII 
 
 
Supplemental Figure VIII: Densitometry analysis of patient and parent plasma does not 
show a defect in VWF multimerization. A) Representative graph of the densitometry of a 
VWF multimer blot (see Figure 3E in main text) of plasma from patient and both 
heterozygous parents compared to normal plasma (NP). Signal intensity was normalized to 
the mean intensity of each sample. B) Analysis of the areas under the curve for peak 1 to 5, 
representing the lower multimers, and peaks 6+, representing the higher multimers. Values 
are normalized to the total area under the curve. Error bars represent SEM, N=3. 
  
Supplemental Figure IX 
 
Supplemental Figure IX. WPB targeting of VAMP3 and VAMP8 is not affected by 
syntaxin-3 deficiency. Healthy control (top panels) and STX3-/- MVID BOECs (bottom 
panels) were fixed after 5-7 days of confluence and immunostained for VWF (red) and WPB 
associated SNARE proteins VAMP3 (A) or VAMP8 (B) (green). 
  
Supplemental Figure X 
 
 
Supplemental Figure X. WPB targeting of P-selectin is not affected by syntaxin-3 
deficiency. Healthy control (top panels) and STX3-/- MVID BOECs (bottom panels) were 
fixed after 5-7 days of confluence and immunostained for VWF (red) and P-selectin (green). 
 
  
Supplemental Figure XI 
 
 
Supplemental Figure XI. WPB targeting of Rab27A and Slp4-a is not affected by 
syntaxin-3 deficiency. Healthy control (top panels) and STX3-/- MVID BOECs (bottom 
panels) were fixed after 5-7 days of confluence and immunostained for VWF (red) and 
Rab27A (A) or Slp4-a (B) (green). 
 
 
Supplemental Figure XII 
 
Supplemental Figure XII. VWF release is impaired in STX3-/- MVID BOECs. A) 
Intracellular VWF levels in healthy control and STX3-/- MVID BOECs. (n=6) B) VWF levels in 
24 hours conditioned medium from control and STX3-/- BOECs. (n=6) C) VWF release from 
control and STX3-/- BOECs after 30 minute stimulation with 100 µM histamine (HIS) or 10 µM 
forskolin + 100 µM IBMX (FSK). Release of VWF is expressed as percentage of intracellular 
VWF (n=6). D) Dose dependency of histamine-stimulated VWF release from control and 
STX3-/- BOECs (n=3). Statistical analyses were performed using paired 2-tailed t-tests (A-D). 
*P<0.05 **P<0.01. Error bars represent SEM. 
  
Supplemental Figure XIII 
 
Supplemental Figure XIII. Syntaxin-3 deficiency affects polarity of release. Control and 
syntaxin-3 deficient MVID BOECs were cultured at confluency for 4-5 days on 0.4 µm pore 
size Transwell inserts. A) Lysates were made to measure intracellular VWF. B-C) Release 
medium was collected from the top (apical) and bottom (basolateral) Transwell 
compartments from unstimulated (B) and histamine (100 µM) stimulated (C) cells. Release of 
VWF/VWFpp is expressed as percentage of intracellular VWF/VWFpp (Bi-ii and Ci-ii) or as a 
percentage of total (apical+basolateral) secretion (Biii-iv and Ciii-iv). Secretion assays were 
performed in triplicate. Error bars respresent SEM.   
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